

Charline Lasnon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10666339/publications.pdf>

Version: 2024-02-01

24
papers

783
citations

623734

14
h-index

610901

24
g-index

24
all docs

24
docs citations

24
times ranked

1067
citing authors

#	ARTICLE	IF	CITATIONS
1	Advances in PET/CT Technology: An Update. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 286-301.	4.6	12
2	Revisiting detection of in-transit metastases in melanoma patients using digital 18F-FDG PET/CT with small-voxel reconstruction. <i>Annals of Nuclear Medicine</i> , 2021, 35, 669-679.	2.2	13
3	New PET technologies “embracing progress and pushing the limits. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2711-2726.	6.4	35
4	End-of-treatment ¹⁸ F-FDG PET/CT in diffuse large B cell lymphoma patients: $\hat{\rho}$ SUV outperforms Deauville score. <i>Leukemia and Lymphoma</i> , 2021, 62, 2890-2898.	1.3	4
5	18F-FDG PET/CT versus Diagnostic Contrast-Enhanced CT for Follow-Up of Stage IV Melanoma Patients Treated by Immune Checkpoint Inhibitors: Frequency and Management of Discordances over a 3-Year Period in a University Hospital. <i>Diagnostics</i> , 2021, 11, 1198.	2.6	1
6	Diagnostic value of baseline 18FDG PET/CT skeletal textural features in follicular lymphoma. <i>Scientific Reports</i> , 2021, 11, 23812.	3.3	6
7	How fast can we scan patients with modern (digital) PET/CT systems?. <i>European Journal of Radiology</i> , 2020, 129, 109144.	2.6	23
8	Baseline 18F-FDG PET radiomic features as predictors of 2-year event-free survival in diffuse large B cell lymphomas treated with immunochemotherapy. <i>European Radiology</i> , 2020, 30, 4623-4632.	4.5	61
9	Comprehensive analysis of the influence of G-CSF on the biodistribution of 18F-FDG in lymphoma patients: insights for PET/CT scheduling. <i>EJNMMI Research</i> , 2019, 9, 79.	2.5	6
10	Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 421-428.	6.4	27
11	Assessment of alteration in liver 18F-FDG uptake due to steatosis in lymphoma patients and its impact on the Deauville score. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 941-950.	6.4	16
12	Reply to: “All that glitters is not gold” new reconstruction methods using Deauville criteria for patient reporting. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 878-881.	6.4	5
13	Does PET Reconstruction Method Affect Deauville Score in Lymphoma Patients?. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1049-1055.	5.0	22
14	Reply to the Letter to the Editor from Peters et al: On the use of the liver as a reference organ for Deauville scoring in lymphoma patients and how it may be affected by liver steatosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2233-2234.	6.4	1
15	Generating harmonized SUV within the EANM EARL accreditation program: software approach versus EARL-compliant reconstruction. <i>Annals of Nuclear Medicine</i> , 2017, 31, 125-134.	2.2	33
16	Impact of the EARL harmonization program on automatic delineation of metabolic active tumour volumes (MATVs). <i>EJNMMI Research</i> , 2017, 7, 30.	2.5	27
17	EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 17-31.	6.4	206
18	EORTC PET response criteria are more influenced by reconstruction inconsistencies than PERCIST but both benefit from the EARL harmonization program. <i>EJNMMI Physics</i> , 2017, 4, 17.	2.7	14

#	ARTICLE	IF	CITATIONS
19	Does PET SUV Harmonization Affect PERCIST Response Classification?. Journal of Nuclear Medicine, 2016, 57, 1699-1706.	5.0	31
20	18F-FDG PET/CT heterogeneity quantification through textural features in the era of harmonisation programs: a focus on lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2324-2335.	6.4	45
21	Patient's weight: a neglected cause of variability in SUV measurements? A survey from an EARL accredited PET centre in 513 patients. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 197-199.	6.4	13
22	The importance of harmonizing interim positron emission tomography in non-Hodgkin lymphoma: focus on the Deauville criteria. Haematologica, 2014, 99, e84-e85.	3.5	22
23	Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 985-996.	6.4	107
24	Impact of Point Spread Function Reconstruction on Thoracic Lymph Node Staging With 18F-FDG PET/CT in Non-Small Cell Lung Cancer. Clinical Nuclear Medicine, 2012, 37, 971-976.	1.3	53